Literature DB >> 10360857

Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery.

A M Bader1, L C Tsen, W R Camann, E Nephew, S Datta.   

Abstract

BACKGROUND: Bupivacaine exists as a mixture of two enantiomers, levobupivacaine and dexbupivacaine. Data suggest that levobupivacaine has equal local anesthetic potency, with reduced potential for central nervous system and cardiovascular toxicity. The present study compares the efficacy of 0.5% levobupivacaine with 0.5% bupivacaine for epidural anesthesia in parturients undergoing elective cesarean delivery.
METHODS: Sixty healthy obstetric patients undergoing elective cesarean delivery with epidural anesthesia completed the study. Patients were randomized to receive 30 ml of either 0.5% levobupivacaine or 0.5% bupivacaine in a double-blind fashion. The efficacy endpoint measures included onset, offset, and quality of anesthesia. Neonatal blood gas analyses, Apgar score determinations, and neurobehavioral examinations were performed. Venous samples for pharmacokinetic studies and serial electrocardiograms were obtained in 10 patients in each group.
RESULTS: Levels of sensory block, motor block, muscle relaxation, and overall quality of anesthesia did not differ between groups. The frequency of hypotension was 84.4% in the levobupivacaine group and 100% for the bupivacaine group (P < or = 0.053). No significant difference in observed maximum concentration of drug after dosing or area under the plasma drug concentration versus time curve were seen. The maximum concentrations were 1.017 and 1.053 microg/ml, and the areas were 4.082 and 3.765 h(microg/ml) for the levobupivacaine and bupivacaine groups, respectively. Umbilical vein-to-maternal vein ratios were 0.303 for the levobupivacaine group and 0.254 for the bupivacaine group.
CONCLUSIONS: The use of epidural 0.5% levobupivacaine for cesarean delivery results in equally efficacious anesthesia compared with 0.5% bupivacaine. Pharmacokinetic parameters were similar in the two groups.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360857     DOI: 10.1097/00000542-199906000-00015

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  11 in total

1.  Placental transfer of bupivacaine enantiomers in normal pregnant women receiving epidural anesthesia for cesarean section.

Authors:  Luciana de Barros Duarte; Elaine Christine Dantas Móises; Ricardo Carvalho Cavalli; Vera Lúcia Lanchote; Geraldo Duarte; Sérgio Pereira da Cunha
Journal:  Eur J Clin Pharmacol       Date:  2007-03-07       Impact factor: 2.953

2.  Lopinavir/ritonavir treatment increases the placental transfer of bupivacaine enantiomers in human immunodeficiency virus-infected pregnant women.

Authors:  Rodrigo Metzker Pereira Ribeiro; Fernanda de Lima Moreira; Elaine Christine Dantas Moisés; Ricardo Carvalho Cavalli; Silvana Maria Quintana; Vera Lucia Lanchote; Geraldo Duarte
Journal:  Br J Clin Pharmacol       Date:  2018-08-02       Impact factor: 4.335

Review 3.  [Levobupivacaine for regional anesthesia. A systematic review].

Authors:  B Urbanek; S Kapral
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

Review 4.  Levobupivacaine: a review of its pharmacology and use as a local anaesthetic.

Authors:  R H Foster; A Markham
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 5.  Levobupivacaine: a review of its use in regional anaesthesia and pain management.

Authors:  Mark Sanford; Gillian M Keating
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

6.  Anesthetic efficacy of bupivacaine solutions in inferior alveolar nerve block.

Authors:  Maria Cristina Volpato; José Ranali; Juliana Cama Ramacciato; Patrícia Cristine de Oliveira; Glaúcia Maria Bovi Ambrosano; Francisco Carlos Groppo
Journal:  Anesth Prog       Date:  2005

7.  Levobupivacaine for epidural anaesthesia and postoperative analgesia in hip surgery: a multi-center efficacy and safety equivalence study with bupivacaine and ropivacaine.

Authors:  T Koch; A Fichtner; U Schwemmer; T Standl; T Volk; K Engelhard; M F Stevens; C Putzke; J Scholz; M Zenz; J Motsch; V Hempel; A Heinrichs; B Zwissler
Journal:  Anaesthesist       Date:  2008-05       Impact factor: 1.041

Review 8.  [Levobupivacaine in obstetric analgesia and anaesthesia. Where is its place?].

Authors:  D H Bremerich; B Zwissler
Journal:  Anaesthesist       Date:  2004-07       Impact factor: 1.041

9.  [Levobupivacaine for parturients undergoing elective caesarean delivery. A dose-finding investigation].

Authors:  D H Bremerich; S Kuschel; N Fetsch; B Zwissler; C Byhahn; D Meininger
Journal:  Anaesthesist       Date:  2007-08       Impact factor: 1.041

Review 10.  Clinical Pharmacokinetics and Pharmacodynamics of Levobupivacaine.

Authors:  Chantal A A Heppolette; Derek Brunnen; Sohail Bampoe; Peter M Odor
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.